Core Insights - DENTSPLY SIRONA Inc. reported a mixed performance for Q4 2025, with adjusted EPS of 27 cents, a 3.8% increase year over year, but missing the Zacks Consensus Estimate by 3.6% [1] - The company experienced a revenue growth of 6.2% year over year, totaling $961 million in the fourth quarter, surpassing estimates by 4.5% [2] - A restructuring plan was announced, aiming for $120 million in annualized cost savings, with a focus on debt reduction and reinvestment in growth initiatives [16][17] Financial Performance - Adjusted EPS for the full year 2025 was $1.60, down 4.6% year over year, while GAAP loss per share was $3.00 compared to $4.48 in the previous year [1] - Total sales for 2025 were reported at $3.68 billion, a decrease of 3% year over year [2] Segment Analysis - Revenues from the Connected Technology Solutions segment were $299 million, reflecting a 1.8% increase but a 1.9% decrease year over year [3] - Essential Dental Solutions segment revenues reached $372 million, up 7.8% year over year [4] - Orthodontic and Implant Solutions segment revenues were $202 million, up 9.8% year over year [4] - Wellspect Healthcare segment revenues totaled $88 million, up 6.9% year over year [5] Geographic Performance - U.S. revenues increased by 14.5% year over year [6] - European revenues rose by 4.8% year over year, but declined by 2.9% at constant currency [6] - Revenues from the Rest of World declined by 0.6% year over year [7] Margin Analysis - Adjusted gross profit improved by 0.4% year over year to $479 million, but the adjusted gross margin contracted by 300 basis points to 49.8% [10] - Adjusted operating profit decreased by 10.4% year over year to $86 million, with an adjusted operating margin of 13.2% [11] Financial Position - The company ended Q4 2025 with cash and cash equivalents of $363 million, unchanged from the previous quarter, and total debt decreased to $2.33 billion [12] - Cumulative net cash from operating activities was $235 million, down from $461 million in the prior year [12] Future Outlook - DENTSPLY SIRONA expects 2026 sales to be between $3.5 billion and $3.6 billion, with adjusted EPS projected in the range of $1.40 to $1.50 [14] - The Zacks Consensus Estimate for 2026 sales is currently $3.67 billion, and for adjusted EPS, it is $1.49 [14] Market Reaction - Shares of DENTSPLY SIRONA rose nearly 7.8% in pre-market trading despite the earnings miss, reflecting investor optimism regarding the restructuring and capital deployment strategy [9][17]

Core Viewpoint - Analysts forecast that Dentsply International (XRAY) will report quarterly earnings of $0.28 per share, reflecting a year-over-year increase of 7.7%, with anticipated revenues of $920.05 million, showing a 1.7% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised 4% lower over the last 30 days, indicating a collective reevaluation by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong relationship between earnings estimate revisions and short-term stock performance [3]. Revenue and Sales Projections - Analysts predict 'Net sales- Essential Dental Solutions' will reach $348.19 million, a change of +0.6% from the prior year [5]. - 'Net sales- Orthodontic and Implant Solutions' are expected to be $196.84 million, indicating a +6.4% change year-over-year [5]. - 'Net sales- Connected Technology Solutions' is projected at $284.22 million, reflecting a -3% change from the previous year [6]. - 'Net sales- Wellspect Healthcare' is estimated to reach $86.48 million, showing a +6.8% change year-over-year [6]. - 'Net sales- Orthodontic and Implant Solutions- Implants & Prosthetics' is expected to be $161.59 million, indicating a -0.3% change [7]. - 'Net sales- Connected Technology Solutions- CAD/CAM' is projected at $128.39 million, reflecting a -9.6% change [7]. - 'Net sales- Connected Technology Solutions- Equipment & Instruments' is forecasted to reach $161.37 million, indicating a +6.9% change [8]. - 'Net sales- Orthodontic and Implant Solutions- Orthodontics' is expected to be $35.14 million, reflecting a significant +52.8% change [8]. - 'Revenues- United States' is projected at $264.91 million, indicating a +2.3% change year-over-year [8]. - 'Revenues- Rest of World' is expected to reach $242.88 million, reflecting a +2.1% change [9]. - 'Revenues- Europe' is estimated at $420.19 million, indicating a +3% change from the previous year [9]. Operating Income - The average prediction for 'Adjusted Operating Income- Connected Technology Solutions' is $20.97 million, compared to $49.00 million reported in the same quarter of the previous year [10]. Stock Performance - Dentsply shares have experienced a +2.9% change in the past month, contrasting with a -0.3% move of the Zacks S&P 500 composite [11].

Core Insights - Dentsply Sirona Inc. reported weaker-than-expected third-quarter earnings and lowered guidance, leading to a decline in stock price [1][7] Financial Performance - Adjusted earnings for the third quarter were 37 cents, down from 50 cents a year ago, but above the consensus estimate of 45 cents [1] - Sales totaled $904 million, a decrease of 5% year over year, yet surpassing the consensus of $896.71 million [2] - Adjusted EBITDA margin improved by 50 basis points to 18.4%, driven by reduced operating expenses, although this was partially offset by lower sales and tariff impacts [2] Segment Performance - Revenues from Connected Technology Solutions fell by 3.9% to $259 million due to lower volumes [2] - Orthodontic and Implant Solutions sales dropped 15% to $205 million, impacted by approximately $30 million from Byte and lower implant volumes in the U.S. and China [3] Strategic Initiatives - The company is implementing a "Return-to-Growth" strategy aimed at delivering sustained, profitable growth over the next 24 months [4] - The board is taking decisive actions to improve performance, as stated by the president and CEO [4] Management Changes - CFO Matt Garth has left the company, with Leslie Varon serving as interim finance chief while a successor is sought [5] Guidance - Fiscal 2025 adjusted earnings guidance has been lowered from $1.80-$2 per share to $1.60, compared to the consensus of $1.88 [6] - The company reaffirmed its 2025 sales guidance of $3.6 billion-$3.7 billion, aligning closely with the consensus of $3.65 billion [6] Market Position - Dentsply Sirona has decided to retain Wellspect as a subsidiary, which focuses on bladder and bowel care products, positioned in a $2 billion addressable market [6][7]

Core Insights - Dentsply International reported $904 million in revenue for Q3 2025, a year-over-year decline of 4.9%, with an EPS of $0.37 compared to $0.50 a year ago, indicating a significant drop in earnings [1] - The revenue exceeded the Zacks Consensus Estimate of $901.59 million by 0.27%, while the EPS fell short of the consensus estimate of $0.45 by 17.78% [1] Revenue Breakdown - Revenue in the United States was $291 million, below the estimated $333.9 million, reflecting a year-over-year decline of 22.2% [4] - Revenue from the Rest of the World reached $231 million, slightly above the estimated $211.1 million, marking a year-over-year increase of 0.4% [4] - European revenue was $382 million, surpassing the average estimate of $360.92 million, with a year-over-year growth of 10.1% [4] Net Sales Performance - Connected Technology Solutions reported net sales of $259 million, slightly above the estimate of $253.17 million, but down 3.7% year over year [4] - Wellspect Healthcare achieved net sales of $83 million, exceeding the estimate of $76.63 million, with a year-over-year increase of 15.3% [4] - Essential Dental Solutions had net sales of $357 million, below the estimate of $367.93 million, reflecting a year-over-year decline of 3.3% [4] - Orthodontic and Implant Solutions reported net sales of $205 million, slightly above the estimate of $202.59 million, with a year-over-year decrease of 14.9% [4] Adjusted Operating Income - Adjusted Operating Income for Connected Technology Solutions was $10 million, significantly below the estimate of $19.2 million [4] - Wellspect Healthcare's Adjusted Operating Income was $28 million, above the average estimate of $24 million [4] - Orthodontic and Implant Solutions reported Adjusted Operating Income of $22 million, exceeding the estimate of $15.66 million [4] - Essential Dental Solutions had Adjusted Operating Income of $116 million, below the estimate of $127.61 million [4] Stock Performance - Dentsply's shares returned +1.9% over the past month, outperforming the Zacks S&P 500 composite's +1.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Dentsply International reported $936 million in revenue for Q2 2025, a year-over-year decline of 4.9%, with an EPS of $0.52 compared to $0.49 a year ago, exceeding the Zacks Consensus Estimate of $933.1 million by 0.31% and delivering an EPS surprise of 4% [1][3] Revenue Performance - Organic sales growth was -4.9%, slightly below the average estimate of -4.6% from six analysts [4] - Revenue in the United States was $293 million, compared to the average estimate of $323.26 million from three analysts [4] - Revenue from the Rest of the World was $239 million, exceeding the average estimate of $222.59 million, representing a year-over-year change of +0.8% [4] - Revenue in Europe was $404 million, surpassing the average estimate of $389.9 million, reflecting a +4.4% change year-over-year [4] Segment Performance - Net sales for Connected Technology Solutions were $243 million, below the estimated $251.55 million, marking a -4% change year-over-year [4] - Net sales for Wellspect Healthcare were $80 million, slightly below the estimate of $81.45 million, with no change year-over-year [4] - Net sales for Essential Dental Solutions were $387 million, exceeding the average estimate of $373.62 million, representing a +3.2% year-over-year change [4] - Net sales for Orthodontic and Implant Solutions were $226 million, slightly above the estimate of $225.94 million, but reflecting an -18.1% change year-over-year [4] Operating Income - Adjusted Operating Income for Connected Technology Solutions was $12 million, below the estimate of $16.97 million [4] - Adjusted Operating Income for Wellspect Healthcare was $25 million, slightly below the estimate of $26.14 million [4] - Adjusted Operating Income for Orthodontic and Implant Solutions was $45 million, significantly above the estimate of $16.63 million [4] - Adjusted Operating Income for Essential Dental Solutions was $151 million, exceeding the average estimate of $126.53 million [4] Stock Performance - Dentsply's shares have returned -17.4% over the past month, contrasting with the Zacks S&P 500 composite's +1.2% change, with a Zacks Rank 2 (Buy) indicating potential outperformance in the near term [3]

Core Insights - Dentsply International reported $879 million in revenue for Q1 2025, a year-over-year decline of 7.8%, with an EPS of $0.43 compared to $0.42 a year ago, indicating a positive surprise of +3.22% over the Zacks Consensus Estimate of $851.55 million and a +48.28% surprise in EPS against the consensus estimate of $0.29 [1] Financial Performance Metrics - Organic sales growth was -4.4%, better than the estimated -8.4% by analysts [4] - Revenue breakdown: - United States: $302 million vs. $305.67 million estimated [4] - Rest of World: $215 million vs. $190.83 million estimated [4] - Europe: $362 million vs. $356.44 million estimated [4] - Year-over-year revenue changes: - Rest of World: -2.7% [4] - Europe: -3.7% [4] - Net sales for Connected Technology Solutions: $235 million vs. $233.14 million estimated, a -4.9% change year-over-year [4] - Net sales for Wellspect Healthcare: $74 million vs. $74.82 million estimated, a +4.2% change year-over-year [4] - Net sales for Essential Dental Solutions: $353 million vs. $352.85 million estimated, a -3% change year-over-year [4] - Net sales for Orthodontic and Implant Solutions: $217 million vs. $193.98 million estimated, a -19.9% change year-over-year [4] Adjusted Operating Income - Adjusted Operating Income for Connected Technology Solutions: $7 million vs. $16.08 million estimated [4] - Adjusted Operating Income for Wellspect Healthcare: $26 million vs. $23.18 million estimated [4] - Adjusted Operating Income for Orthodontic and Implant Solutions: $37 million vs. $13.19 million estimated [4] - Adjusted Operating Income for Essential Dental Solutions: $135 million vs. $117.25 million estimated [4] Stock Performance - Dentsply's shares returned +0.2% over the past month, underperforming the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance in the near term [3]

Core Viewpoint - Dentsply International (XRAY) is expected to report a significant decline in quarterly earnings and revenues, with earnings per share projected at $0.29, a 31% decrease year-over-year, and revenues forecasted at $851.55 million, reflecting a 10.7% decline compared to the previous year [1] Earnings Estimates - The consensus EPS estimate has been revised downward by 1.5% over the past 30 days, indicating a collective reassessment by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3] Key Metrics Projections - Analysts project 'Net sales- Connected Technology Solutions' to reach $233.14 million, a year-over-year decrease of 5.6% [5] - 'Net sales- Wellspect Healthcare' is expected to be $74.82 million, indicating a 5.4% increase from the same quarter last year [5] - 'Net sales- Essential Dental Solutions' is forecasted at $352.85 million, reflecting a 3.1% decline year-over-year [5] - 'Net sales- Orthodontic and Implant Solutions' is estimated to be $193.98 million, a significant decrease of 28.4% from the previous year [6] - 'Revenues- Rest of World' is projected at $190.83 million, down 13.7% year-over-year [6] - 'Revenues- Europe' is expected to be $356.44 million, indicating a 5.2% decline from the year-ago quarter [6] Stock Performance - Over the past month, Dentsply shares have returned +5.6%, underperforming the Zacks S&P 500 composite, which has seen a +10.6% change [7] - Currently, Dentsply carries a Zacks Rank 4 (Sell), suggesting potential underperformance in the near future [7]